VTRS · Earnings call · 2026Q2T · Full report
Estradiol Capacity Expansion
Viatris Inc · 2026-08-06 · Importance 40 · Surprise 42 · In source text
Demand for Viatris’s estradiol hormone-replacement patches increased sharply after the FDA removed a black-box warning at the end of 2025. Management said the Vermont facility produces next-generation transdermal systems and that capacity is being increased to meet demand. Viatris is currently able to fulfill approximately 70% of estradiol-patch orders. The company expects the demand expansion to persist and views the product as a potential revenue driver through 2030, supported by investment in internal and external production capacity.
Key facts
- Viatris is developing a progestin-only patch that has completed Phase III enrollment with topline results expected in the first half of 2027
- Viatris expects to continue investing to meet increased demand for estradiol patches through 2030 and considers it a material revenue driver through that period
- Viatris is increasing capacity at Vermont facility that produces transdermal systems and expects to remain a major leader in the estradiol patch market
- Viatris is currently able to fulfill about 70% of estradiol patch orders
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Viatris is developing a progestin-only patch that has completed Phase III enrollment with topline results expected in the first half of 2027 |
| cash | negative | committed | — | Viatris is increasing capacity at Vermont facility that produces transdermal systems and expects to remain a major leader in the estradiol… |
| revenue | positive | probable | — | Viatris is increasing capacity at Vermont facility that produces transdermal systems and expects to remain a major leader in the estradiol… |